Cargando…

Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer

SIMPLE SUMMARY: The psoas muscle mass index (PMI) is a simplified tool used in the quantification of skeletal muscle. The aim of our study was to investigate whether the PMI at diagnosis or its decrease during chemotherapy can influence the prognosis of unresectable pancreatic cancer. The median ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwai, Naoto, Okuda, Takashi, Oka, Kohei, Sakagami, Junichi, Harada, Taishi, Ohara, Tomoya, Hattori, Chie, Taniguchi, Masashi, Sakai, Hiroaki, Hara, Tasuku, Tsuji, Toshifumi, Komaki, Toshiyuki, Kagawa, Keizo, Dohi, Osamu, Yasuda, Hiroaki, Itoh, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345635/
https://www.ncbi.nlm.nih.gov/pubmed/34359761
http://dx.doi.org/10.3390/cancers13153860
_version_ 1783734676180959232
author Iwai, Naoto
Okuda, Takashi
Oka, Kohei
Sakagami, Junichi
Harada, Taishi
Ohara, Tomoya
Hattori, Chie
Taniguchi, Masashi
Sakai, Hiroaki
Hara, Tasuku
Tsuji, Toshifumi
Komaki, Toshiyuki
Kagawa, Keizo
Dohi, Osamu
Yasuda, Hiroaki
Itoh, Yoshito
author_facet Iwai, Naoto
Okuda, Takashi
Oka, Kohei
Sakagami, Junichi
Harada, Taishi
Ohara, Tomoya
Hattori, Chie
Taniguchi, Masashi
Sakai, Hiroaki
Hara, Tasuku
Tsuji, Toshifumi
Komaki, Toshiyuki
Kagawa, Keizo
Dohi, Osamu
Yasuda, Hiroaki
Itoh, Yoshito
author_sort Iwai, Naoto
collection PubMed
description SIMPLE SUMMARY: The psoas muscle mass index (PMI) is a simplified tool used in the quantification of skeletal muscle. The aim of our study was to investigate whether the PMI at diagnosis or its decrease during chemotherapy can influence the prognosis of unresectable pancreatic cancer. The median overall survival (OS) was 278.0 (95% confidence interval (CI), 199.1–356.9) days in the high-PMI group, and 221.0 (95% CI, 90.9–351.1) days in the low-PMI group (p = 0.329). The median OS was 347.0 (95% CI, 289.1–404.9) days in the group without PMI decrease and 172.0 (95% CI, 129.8–214.2) days in the group with PMI decrease (p = 0.001). We determined that the PMI at diagnosis was not associated with OS in patients with unresectable pancreatic cancer receiving systemic chemotherapy, whereas PMI decrease during chemotherapy influenced the OS. ABSTRACT: The impact of the psoas muscle mass index (PMI) on survival is still poorly understood in unresectable pancreatic cancer. Thus, we aimed to investigate whether the PMI at diagnosis or its decrease during chemotherapy can influence the prognosis of unresectable pancreatic cancer. The data of 100 patients were analyzed, and they were divided into two groups according to the median PMI in each sex. Subsequently, 72 patients undergoing computed tomography (CT) within 30–100 days from CT at diagnosis were evaluated in terms of PMI change rate, and divided into two groups based on the median. We evaluated the clinical characteristics and outcomes in terms of the PMI at diagnosis or its decrease during chemotherapy. The median PMI was 5.00 in males, and 3.66 in females. The median overall survival (OS) was 278.0 days in the high-PMI group and 221.0 days in the low-PMI group (p = 0.329). The median PMI change rate was −2.4%. The median OS was 347.0 days in the group without PMI decrease and 172.0 days in the group with PMI decrease (p = 0.001). We determined that a pivotal prognostic factor was not the PMI at diagnosis, but rather PMI decrease during chemotherapy in unresectable pancreatic cancer.
format Online
Article
Text
id pubmed-8345635
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83456352021-08-07 Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer Iwai, Naoto Okuda, Takashi Oka, Kohei Sakagami, Junichi Harada, Taishi Ohara, Tomoya Hattori, Chie Taniguchi, Masashi Sakai, Hiroaki Hara, Tasuku Tsuji, Toshifumi Komaki, Toshiyuki Kagawa, Keizo Dohi, Osamu Yasuda, Hiroaki Itoh, Yoshito Cancers (Basel) Article SIMPLE SUMMARY: The psoas muscle mass index (PMI) is a simplified tool used in the quantification of skeletal muscle. The aim of our study was to investigate whether the PMI at diagnosis or its decrease during chemotherapy can influence the prognosis of unresectable pancreatic cancer. The median overall survival (OS) was 278.0 (95% confidence interval (CI), 199.1–356.9) days in the high-PMI group, and 221.0 (95% CI, 90.9–351.1) days in the low-PMI group (p = 0.329). The median OS was 347.0 (95% CI, 289.1–404.9) days in the group without PMI decrease and 172.0 (95% CI, 129.8–214.2) days in the group with PMI decrease (p = 0.001). We determined that the PMI at diagnosis was not associated with OS in patients with unresectable pancreatic cancer receiving systemic chemotherapy, whereas PMI decrease during chemotherapy influenced the OS. ABSTRACT: The impact of the psoas muscle mass index (PMI) on survival is still poorly understood in unresectable pancreatic cancer. Thus, we aimed to investigate whether the PMI at diagnosis or its decrease during chemotherapy can influence the prognosis of unresectable pancreatic cancer. The data of 100 patients were analyzed, and they were divided into two groups according to the median PMI in each sex. Subsequently, 72 patients undergoing computed tomography (CT) within 30–100 days from CT at diagnosis were evaluated in terms of PMI change rate, and divided into two groups based on the median. We evaluated the clinical characteristics and outcomes in terms of the PMI at diagnosis or its decrease during chemotherapy. The median PMI was 5.00 in males, and 3.66 in females. The median overall survival (OS) was 278.0 days in the high-PMI group and 221.0 days in the low-PMI group (p = 0.329). The median PMI change rate was −2.4%. The median OS was 347.0 days in the group without PMI decrease and 172.0 days in the group with PMI decrease (p = 0.001). We determined that a pivotal prognostic factor was not the PMI at diagnosis, but rather PMI decrease during chemotherapy in unresectable pancreatic cancer. MDPI 2021-07-31 /pmc/articles/PMC8345635/ /pubmed/34359761 http://dx.doi.org/10.3390/cancers13153860 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Iwai, Naoto
Okuda, Takashi
Oka, Kohei
Sakagami, Junichi
Harada, Taishi
Ohara, Tomoya
Hattori, Chie
Taniguchi, Masashi
Sakai, Hiroaki
Hara, Tasuku
Tsuji, Toshifumi
Komaki, Toshiyuki
Kagawa, Keizo
Dohi, Osamu
Yasuda, Hiroaki
Itoh, Yoshito
Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer
title Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer
title_full Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer
title_fullStr Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer
title_full_unstemmed Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer
title_short Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer
title_sort depletion of psoas muscle mass after systemic chemotherapy is associated with poor prognosis in patients with unresectable pancreatic cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345635/
https://www.ncbi.nlm.nih.gov/pubmed/34359761
http://dx.doi.org/10.3390/cancers13153860
work_keys_str_mv AT iwainaoto depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT okudatakashi depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT okakohei depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT sakagamijunichi depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT haradataishi depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT oharatomoya depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT hattorichie depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT taniguchimasashi depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT sakaihiroaki depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT haratasuku depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT tsujitoshifumi depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT komakitoshiyuki depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT kagawakeizo depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT dohiosamu depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT yasudahiroaki depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer
AT itohyoshito depletionofpsoasmusclemassaftersystemicchemotherapyisassociatedwithpoorprognosisinpatientswithunresectablepancreaticcancer